Greenyn Biotechnology Co., Ltd
6846.TWO · Taipei Exchange · TWD
49,00TWD
−1,50 (−2,97 %)Stand 10. Nov., 5:30
Kennzahlen
- Eröffnung
- 49,50
- Vortag
- 50,50
- Tagesspanne
- 45,95 – 50,00
- 52 Wochen
- 45,95 – 78,00
- Volumen
- 83.635
- Ø Volumen
- 13.369
- Börsenwert
- 1,33 Mrd. TWD
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 0,1
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary supplements, dedicated to the development, production, and worldwide distribution of health-enhancing products. Their product portfolio includes a range of proprietary active ingredients. These feature notable components such as Insumate, derived from bitter melon extract; Antromax, which utilizes antrodia cinnamomea; and the Zymologist 101 Phyto fermented drink. Beyond individual ingredients, Greenyn provides an extensive selection of functional product series catering to a diverse array of health and wellness needs. These encompass solutions for youth and beauty, digestive and brain health, overall body regulation, throat care, hair care, vision support, and various lifestyle enhancement formulas. Additional ranges include joint health, general nutritional and energy supplementation, immune modulation, low-burden options, sleep assistance, body contouring, circulatory support, specific formulas for men's vitality and women's intimate health, and dedicated products for mature women. Moreover, the company extends its expertise through various services, including custom product development, Original Design Manufacturing (ODM), dosage form optimization, and application support. Established in 2012, the firm's operations are headquartered in Taichung, Taiwan.
- CEO
- Pang Kuei Hsu
- Mitarbeitende
- 143
- Hauptsitz
- Taichung, TX, TW
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 19. Apr. 2022
- Website
- greenynbio.com
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.